Weigh! The second alternative to novovir - "weilide" listed in China

December 9, 2018 / Meitong news agency / -- Gilead Science Co., Ltd (NASDAQ Stock Code: gild) announced that the slow hepatitis B drug viride ® (propofol tenofovir fumarate tablets) approved in China on November 8 was officially listed Viride ® (TAF, 25mg in propofol tenofovir) can be used to treat chronic hepatitis B (HBV) in adults and adolescents (over 12 years old and weighing at least 35kg) In the past decade, Verizon is the only new hepatitis B drug approved by the FDA From then on, Chinese patients with chronic hepatitis B will be able to obtain global innovative drugs simultaneously Zhuang Hui, academician of Chinese Academy of engineering, said at the listing meeting: "it is estimated that there are about 86 million hepatitis B carriers in China, accounting for about 1 / 3 of the global infected population [1], [2] If there is no antiviral treatment for chronic hepatitis B patients, it is estimated that about 10 million people will die of hepatitis B related cirrhosis and liver cancer from 2015 to 2030 [3] With the increase of hepatitis B vaccination coverage, the number of people infected with hepatitis B in China decreased significantly However, the status of diagnosis and treatment is still not optimistic 1 / 3 of the patients with chronic hepatitis B do not know that there are effective anti HBV drugs [4], more than half of the patients with chronic hepatitis B have never been given standard antiviral treatment [4], and more than 60% of the patients with chronic hepatitis B have stopped taking drugs before they have reached the standard of stopping taking drugs [4] Knowing hepatitis B and standardizing treatment are the key to improve the diagnosis and treatment rate, and also the important premise for us to achieve the goal of eliminating hepatitis B by 2030 proposed by who Effective antiviral treatment can delay the progress of the disease "Although it is not yet able to completely eliminate the virus, with the upgrading of antiviral drugs in China, chronic hepatitis B patients with long-term treatment can have a very low drug resistance rate and better safety protection of drug choice, reducing the risk of liver cancer," said Professor Ren Hong, Dean of the Second Affiliated Hospital of Chongqing Medical University, who said: "the" target "liver of velide ® can effectively resist the virus and kidney Compared with the bone safety laboratory parameters, tenofovir fumarate (TDF) has a higher recovery rate of transaminase (recovery rate of liver function cells after antiviral treatment), which provides a new hope for patients with hepatitis B "In just two years since Gilead entered China, it has brought several global leading innovative drugs in the field of liver diseases to Chinese patients," said Luo Yongqing, global vice president of Gilead science and general manager of China "The listing of velide ® in China has fulfilled Gilead science's commitment to Chinese patients In the future, we will continue to actively introduce more innovative therapies to help meet the health needs of Chinese patients " On the same day of the conference, Taikang care for patients with chronic hepatitis B was released at the same time Gilead science and Taikang Insurance Group will take improving the health benefits of patients as their common goal, and work together to provide more effective and safer treatment, more comprehensive health management and risk protection for the majority of Chinese patients Liu Hongbo, head of Taikang endowment health insurance, said at the meeting: "the two sides will explore and try a comprehensive health management security model with Chinese characteristics, and commit to combine" better medicine + more standardized health management + more professional risk security "to provide innovative diagnosis and treatment solutions for Chinese patients with chronic hepatitis B, and contribute to the great goal of healthy China 2030 Responsibility [1] Polaris Observatory Collaborators Lancet Gastroenterol Hepatol 2018 Jun;3(6):383-403 [2] Chen S, et al Lancet 2018 Apr 21; 391(10130):1572 [3] WHO Up to 10 million people in China could die from chronic hepatitis by 2030-urgent action needed to bring an end to the  ‘silent epidemic’ 2016 http://www.wpro.who.int/china/mediacentre/releases/2016/20160727-china-world-hepatitis-day/en/   (accessed.Oct 26, 2018) [4] Yan YP, Et al Copyright © 2018 Gilead science, Inc All Rights Reserved Gilead science is a biopharmaceutical company that discovers, develops and commercializes innovative therapies in areas of unmet medical needs The company's mission is to improve and simplify the treatment of patients with serious diseases around the world Gilead operates in more than 35 countries around the world and is headquartered in foster, California.